Breaking News

Trials & Filings in Brief: Oct. 31, 2013

By Gil Roth | October 31, 2013

Ariad, Baxter, e-Therapeutics, Hyperion, Kamada, Mesoblast, Stem Cell Therapeutics, Teva

Phase I
Kamada reports preliminary pediatric diabetes data . . . read more

Phase II
e-Therapeutics starts trial of tramadol CR formulation . . . read more

Phase III
Teva gets approval for CHF trial . . . read more

Post-Approval
Hyperion begins UCD outcomes study . . . read more

Filings
Ariad suspends Iclusig marketing in U.S. . . . read more

Baxter submits Rixubis in EU . . . read more

Stem Cell Therapeutics gets Orphan status for tigecycline in AML . . . read more

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important